Benralizumab + Placebo

Phase 2/3Completed

0 views this week 0 watching💤 Quiet

Interest: 38/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Eosinophilic Gastritis or Gastroenteritis

Conditions

Eosinophilic Gastritis or Gastroenteritis

Trial Timeline

Apr 23, 2018 → Jan 12, 2022

NCT ID

NCT03473977

About Benralizumab + Placebo

Benralizumab + Placebo is a phase 2/3 stage product being developed by AstraZeneca for Eosinophilic Gastritis or Gastroenteritis. The current trial status is completed. This product is registered under clinical trial identifier NCT03473977. Target conditions include Eosinophilic Gastritis or Gastroenteritis.

What happened to similar drugs?

6 of 17 similar drugs in Eosinophilic Gastritis or Gastroenteritis were approved

Approved (6) Terminated (2) Active (9)

🔄Tezepelumab + TezepelumabAstraZenecaPhase 3

✅BenralizumabAstraZenecaApproved

❌Benralizumab + Matching placeboAstraZenecaPhase 3

🔄BenralizumabAstraZenecaPhase 3

🔄Benralizumab + Mepolizumab + Placebo to Mepolizumab + Placebo to BenralizumabAstraZenecaPhase 3

✅Benralizumab Prefilled SyringeAstraZenecaApproved

🔄Benralizumab + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05692180	Phase 3	Recruiting	Apr 5, 2023	May 16, 2032	Asthma
NCT05251909	Phase 3	Terminated	Jan 18, 2022	Feb 13, 2024	Eosinophilic Gastritis
NCT04612790	Phase 3	Terminated	Mar 31, 2021	Oct 26, 2023	Bullous Pemphigoid
NCT04191304	Phase 3	Active	Jul 20, 2020	Dec 30, 2026	Hypereosinophilic Syndrome
NCT04185012	Phase 3	Completed	Feb 24, 2020	Jun 28, 2024	Nasal Polyps
NCT03953300	Approved	Active	Oct 8, 2019	Oct 19, 2026	Asthma
NCT04053634	Phase 3	Completed	Aug 26, 2019	Jul 28, 2025	Chronic Obstructive Pulmonary Disease
NCT03470311	Phase 3	Completed	Apr 26, 2018	Nov 30, 2022	Severe Prednisone Dependent Eosinophilic Asthma
NCT03473977	Phase 2/3	Completed	Apr 23, 2018	Jan 12, 2022	Eosinophilic Gastritis or Gastroenteritis
NCT03186209	Phase 3	Completed	Sep 7, 2017	Jan 30, 2023	Asthma
NCT02322775	Phase 3	Completed	Feb 2, 2015	Oct 7, 2015	Asthma
NCT01947946	Phase 3	Terminated	Nov 1, 2013	Jul 1, 2014	Asthma
NCT01928771	Phase 3	Completed	Sep 19, 2013	Apr 5, 2016	Asthma
NCT01914757	Phase 3	Completed	Aug 1, 2013	Mar 1, 2016	Asthma

Competing Products

20 competing products in Eosinophilic Gastritis or Gastroenteritis

See all competitors

Product	Company	Stage	Hype Score
KHK4563 + KHK4563 + KHK4563 + Placebo	Kyowa Kirin	Phase 2	35
benralizumab + benralizumab + Placebo	Kyowa Kirin	Phase 2	35
SHR-1703 + SHR-1703 Placebo	Jiangsu Hengrui Medicine	Phase 2	35
NS-229 + Placebo	Nippon Shinyaku	Phase 2	42
Esomeprazole + Budesonide	AstraZeneca	Phase 2/3	38
Tezepelumab + Tezepelumab	AstraZeneca	Phase 3	44
Benralizumab	AstraZeneca	Approved	43
Cohort	AstraZeneca	Pre-clinical	26
Benralizumab + Matching placebo	AstraZeneca	Phase 3	32
Benralizumab	AstraZeneca	Phase 3	44
Benralizumab + Mepolizumab + Placebo to Mepolizumab + Placebo to Benralizumab	AstraZeneca	Phase 3	44
Benralizumab Prefilled Syringe	AstraZeneca	Approved	50
benralizumab	AstraZeneca	Pre-clinical	33
Benralizumab + Placebo	AstraZeneca	Phase 3	44
Benralizumab	AstraZeneca	Phase 3	47
Benralizumab + Placebo	AstraZeneca	Phase 3	32
Tezepelumab + Placebo	AstraZeneca	Phase 2	42
inhaled/swallowed budesonide + viscous/swallowed budesonide	AstraZeneca	Pre-clinical	26
Benralizumab + 129 Xenon	AstraZeneca	Pre-clinical	30
Benralizumab + Placebo	AstraZeneca	Phase 3	40